- Report
- March 2024
- 149 Pages
Global
From €4754EUR$4,950USD£4,059GBP
- Report
- June 2023
- 171 Pages
Global
From €5282EUR$5,500USD£4,510GBP
- Report
- December 2023
- 146 Pages
Global
From €4274EUR$4,450USD£3,649GBP
Cologuard is a non-invasive diagnostic test used to detect colorectal cancer and precancerous polyps. It is a stool-based test that uses DNA markers to detect the presence of cancerous and precancerous cells in the colon. Cologuard is the first and only FDA-approved stool-based test for colorectal cancer screening. It is designed to be used as an alternative to traditional colonoscopy, which is an invasive procedure.
Cologuard is a relatively new technology in the field of diagnostics, and is gaining traction as an effective and convenient way to screen for colorectal cancer. It is becoming increasingly popular among healthcare providers and patients alike, as it is a non-invasive and cost-effective way to screen for colorectal cancer.
Some companies in the Cologuard market include Exact Sciences, Genomic Health, and Guardant Health. Show Less Read more